Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles - 2December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- 3Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- 4Web designers for Independent ventures
- 5Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Putting resources into Yourself: Self-awareness Techniques
- Building an Individual Brand: Illustrations from Powerhouses
- Aid sent by ambulance to Ukraine front line
- Israel scales back use of top missile interceptors as Iran barrages persist
- Fire Allegedly Triggered by Wedding Cake Sparkler Causes Venue to Go Up in Flames, Leaving Groom with Second-Degree Burns
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
- At least 11 killed in South Africa mass shooting
- An Aide On Upgrading Your FICO rating
